 |
7 Companies | 6 Products |
|
|
6 Products | |
29 Diseases | |
11 Trials |  |
763 News |  |
| 12345678910111213...134135» |
- | Journal: UK5099 Inhibits the NLRP3 Inflammasome Independently of its Long-Established Target Mitochondrial Pyruvate Carrier. (Pubmed Central) - Sep 27, 2024
Importantly, structure modification reveals that the inhibitory activities of UK5099 on NLRP3 are unrelated to the existence of the activated double bond within the UK5099 molecule. Thus, this study uncovers a previously unknown molecular target for UK5099, which not only offers a new candidate for the treatment of NLRP3-driven diseases but also confounds its use as an MPC inhibitor in immunometabolism studies.
- | Preclinical, Journal: Wuwei Kushen Changrong capsule alleviates DSS-induced colitis in mice via inhibition of NLRP3 inflammasome and STAT3 pathway. (Pubmed Central) - Sep 27, 2024
The mechanisms through which CSCC protects against DSS-induced colitis may include upregulating Gpr43, inhibiting the STAT3/NLRP3 pathway, and suppressing inflammation factors like IL-17A. These findings highlight the mechanisms underlying CSCC's anti-colitis effects and suggest its potential as a therapeutic candidate for managing the progression of UC.
- | Journal: Every-other-day fasting inhibits pyroptosis while regulating bile acid metabolism and activating TGR5 signaling in spinal cord injury. (Pubmed Central) - Sep 27, 2024
Notably, EODF promoted the secretion of bile acid metabolites, activated TGR5, and inhibited the NLRP3/Caspase-1/GSDMD pyroptosis pathway and inflammation in these rats. In summary, EODF could mitigate secondary injury after SCI and foster functional recovery by improving metabolism, activating the TGR5 signaling and inhibiting the NLRP3 pyroptosis pathway.
- | Preclinical, Journal: Genistein inhibits Nlrp3/caspase-1 signalling to alleviate traumatic brain injury-induced anxiety-like behaviours in rats. (Pubmed Central) - Sep 27, 2024
In summary, EODF could mitigate secondary injury after SCI and foster functional recovery by improving metabolism, activating the TGR5 signaling and inhibiting the NLRP3 pyroptosis pathway. Genistein alleviates anxiety-like behaviours in TBI rats, which may be mediated via inhibiting Nlrp/caspase-1 signalling pathway.
- | Journal: Irisin Prevents Cell Death in High Glucose via NLRP3 Inhibition. (Pubmed Central) - Sep 26, 2024
We found the protective effect of irisin on apoptosis and pyroptosis was abolished by NLRP3 over-expression. Our data suggest that irisin protects CMECs against apoptosis and pyroptosis, at least in part, by inhibiting NLRP3 inflammasome.
- || Review, Journal: The NLRP3 inflammasome in allergic diseases: mechanisms and therapeutic implications. (Pubmed Central) - Sep 26, 2024
As preliminarily demonstrated, specific NLRP3 inflammatory vesicle inhibitors play refectory roles in animal models of allergic diseases, and it is believed that specific NLRP3 inflammasome inhibitors may be potential therapeutic agents for allergic diseases. This review highlights the progress of research on the NLRP3 inflammasome in allergic diseases, explores its contribution to different types of allergic diseases, and identifies promising clinical targets for intervention.
- | Preclinical, Journal: Diallyl trisulfide alleviates dextran sulphate sodium-induced colitis in mice by inhibiting NLRP3 inflammasome activation via ROS/Trx-1 pathway. (Pubmed Central) - Sep 26, 2024
Trx-1 overexpression and interference in macrophages promoted and diminished NLRP3 inflammasome activation, respectively. In summary, garlic and its main active ingredient DATS have potentials to prevent and treat UC, and DATS functions by inhibiting NLRP3 inflammasome activation via Trx-1/ROS pathway.
- | Journal: Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen. (Pubmed Central) - Sep 26, 2024
Crucially, with acceptable mouse pharmacokinetic profiles, Z48 demonstrated notable therapeutic efficacy in a mouse model of DSS-induced ulcerative colitis, while displaying no significant therapeutic impact on NLRP3KO mice. In conclusion, this study provided a promising NLRP3 inflammasome inhibitor with novel molecular scaffold, poised for further development as a therapeutic candidate in the treatment of inflammatory bowel disease.
- | Preclinical, Journal: Total glucosides of paeony inhibit NLRP3/caspase-1/GSDMD-mediated inflammation and pyroptosis in C3H/HeJ alopecia areata mice. (Pubmed Central) - Sep 25, 2024
TGP suppresses the NLRP3/caspase-1/GSDMD signaling cascade in the skin tissues of AA mice, thereby reducing cellular pyroptosis and inflammation. TGP may be a potential therapeutic agent for AA.
- | Journal: ?-3 PUFAs Ameliorated the Maternal High-Fructose Diet-Induced Early-Onset Retinopathy in Offspring via Inhibiting NLRP3-Associated Neuroinflammation. (Pubmed Central) - Sep 25, 2024
Together, these results indicate that the early onset and extensive retinal dysfunction may be a result of glial activation which is induced by maternal HFD to initiate an inflammatory microenvironment leading to a long-term progression of retinopathy. Short-term administration of ?-3 PUFA at a young age may be a feasible strategy to intervene in the maternal HFD-programmed retinal impairment in male offspring.
- | Bay11-7082 / Bayer
Journal: ?-amanitin induce inflammatory response by activating ROS/NF-?B-NLRP3 signaling pathway in human hepatoma HepG2 cells. (Pubmed Central) - Sep 25, 2024
These results demonstrated that AMA could induce inflammation through activating the NLRP3 inflammasome triggered by ROS/NF-?B signaling pathway. Our research provides new insights into the molecular mechanism of AMA-induced inflammation damage and may contribute to establish new prevention strategies for AMA hepatotoxicity.
- TGF-? Activated Kinase 1 Inhibition by Pentagalloyl Glucose Inhibits NLRP3 Inflammasome Formation and Ameliorates MSU-Induced Inflammation (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1833;
PGG significantly reduced MSU-induced proinflammatory mediators and inhibited the formation of NLRP3 inflammasomes. Our finding suggests that treatment with TAK1 inhibitors may help reduce the onset and severity of acute gout flares.
- NLRP3 Inflammasome Promotes Release of Peptidyl Arginine Deiminases2 and 4 from Human Neutrophils (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1807;
We demonstrated cell death-independent release of PAD2 and PAD4 and identified NLRP3 inflammasome activation as a trigger promoting PAD release in human whole blood and neutrophils. Our data further suggest a role for NLRP3 inflammasome in amplifying the autoimmune response in RA.
- dapansutrile (OLT1177) / Olatec Therap
Screening NLRP3 Drug Candidates in Clinical Development:Lessons from Existing and Emerging Technologies (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1805;
P2, P2/3
The most clinically relevant promise of NLRP3 inhibitors as an emerging new therapeutic class is to safely control inflammation when administered chronically. Although new screening technologies such as NanoBRET
- | Journal: Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors. (Pubmed Central) - Sep 24, 2024
Although new screening technologies such as NanoBRET Mechanistic studies indicated that compound 19 directly targets the NLRP3 protein (KD: 0.45
- | Journal: Scaffold hopping-driven optimization for the identification of NLRP3 inhibitors as potential gout therapeutics. (Pubmed Central) - Sep 24, 2024
Finally, compound 23 showed good anti-inflammatory and analgesic effects in acute peritonitis and arthritis. Overall, the present study provides NLRP3 inhibitors with favorable pharmacological properties, which may not only serve as a tool molecule for studying NLRP3-related functions, but also may further facilitate the gout treatment.
- | Journal: Yang-Gan-Jiang-Mei formula alleviates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome through mitophagy. (Pubmed Central) - Sep 24, 2024
In addition, YGJM formula exhibited the promotion of PINK1/parkin-mediated mitophagy, which could perturb NLRP3 inflammasome activation, and as a result, the hepatocyte inflammation was also suppressed both in vitro and in vivo. Our preliminary results indicate that YGJM formula can ameliorate NASH mechanistically by interfering with PINK1/parkin-mediated mitophagy and NLRP3 inflammasome to exert anti-inflammation ability and promote mitochondrial function restoration.
- | Journal: Hypericum sampsonii ameliorates radiodermatitis by inhibiting NLRP3 inflammasome activation. (Pubmed Central) - Sep 23, 2024
H. sampsonii may inhibit NLRP3 inflammatory vesicle activation via interfering with TLR4/NF-?B signaling to reduce the inflammatory response in macrophages and thus play a role in the treatment of RD.
- | Journal: Functional Characterization of an Arylsulfonamide-Based Small-Molecule Inhibitor of the NLRP3 Inflammasome. (Pubmed Central) - Sep 22, 2024
and IL-10 upon the activation of the NLRP3 inflammasome. Collectively, our studies support the functional activities of YM-I-26 as a NLRP3 inhibitor in physiologically relevant cell models, and warrant future studies of YM-I-26 and its analogs to advance the drug development as potential therapeutics.
- || Kineret (anakinra) / SOBI
Review, Journal: Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome pathway in diabetes: mechanistic insights and therapeutic implications. (Pubmed Central) - Sep 21, 2024
Targeting the NLRP3 inflammasome, thus, presents a promising strategy for managing diabetes and its complications, with oral hypoglycemic drugs offering dual benefits of glycemic control and inflammation reduction. Further research into the specific mechanisms and long-term effects of these drugs on NLRP3 inflammasome activity is warranted.
- | Journal: Deep-Learning-Driven Discovery of SN3-1, a Potent NLRP3 Inhibitor with Therapeutic Potential for Inflammatory Diseases. (Pubmed Central) - Sep 21, 2024
Furthermore, SN3-1 demonstrated significant therapeutic efficacy in various disease models characterized by NLRP3 activation. This study introduces a potent candidate for developing NLRP3 inhibitors and significantly expands the repertoire of tools available for the discovery of novel inhibitors.
- | Ibrance (palbociclib) / Pfizer
Journal: Double-stranded DNA enhances platelet activation, thrombosis, and myocardial injury via cyclic GMP-AMP synthase. (Pubmed Central) - Sep 21, 2024
This study introduces a potent candidate for developing NLRP3 inhibitors and significantly expands the repertoire of tools available for the discovery of novel inhibitors. These results suggested that dsDNA is a novel driver of platelet activation and thrombus formation in STEMI patients.
- | Preclinical, Journal: EGCG alleviates Ochratoxin A-induced pyroptosis in rat's kidney by inhibiting NLRP3/Caspase-1/GSDMD signaling pathway. (Pubmed Central) - Sep 21, 2024
NLRP3/Caspase-1/GSDMD pathway is induced in the kidneys due to OTA exposure were shown with this study. Potent antioxidant EGCG could alleviate the pathways specified with this study in OTA nephrotoxicity and its supplementation may be effective strategies for the protection.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal: Astragaloside IV attenuates fatty acid-induced renal tubular injury in diabetic kidney disease by inhibiting fatty acid transport protein-2. (Pubmed Central) - Sep 21, 2024
Potent antioxidant EGCG could alleviate the pathways specified with this study in OTA nephrotoxicity and its supplementation may be effective strategies for the protection. Astragaloside IV exerts antioxidant and anti-inflammatory effects in diabetic kidney disease by inhibiting FATP2-mediated fatty acid transport, thereby attenuating renal tubular injury.
- | Journal: Melatonin downregulates angiogenesis and lymphangiogenesis by regulating tumor-associated macrophages via NLRP3 inflammasomes in lung adenocarcinoma. (Pubmed Central) - Sep 20, 2024
Melatonin protected against the TAMs- and NLRP3 axis-associated promotion of the aforementioned events in vitro and in vivo. Hence, melatonin is a promising candidate for managing for tumor-related angiogenesis and lymphangiogenesis in lung adenocarcinoma.
- | Journal: AdipoRon exerts an antidepressant effect by inhibiting NLRP3 inflammasome activation in microglia via promoting mitophagy. (Pubmed Central) - Sep 17, 2024
Importantly, inhibition of mitophagy attenuated the antidepressant and neuroprotective effects of AdipoRon. Overall, these findings indicate that AdipoRon alleviates depression by inhibiting NLRP3 inflammasome activation in microglia via improving mitophagy.
- | RSL3 / Stanford University
Journal: Carthamin yellow alleviates dextran sodium sulfate-induced ulcerative colitis by repairing the intestinal barrier and activating the Nrf2/GPX4 axis. (Pubmed Central) - Sep 17, 2024
Further analyses revealed that CY could inhibit ferroptosis via the Nrf2/GPX4 axis in both in vivo and RSL3-induced Caco-2 cell models...CY might be a potential candidate for the treatment of UC. Therefore, our results provide an important reference for investigating the mechanisms of flavonoid compounds involved in preventing inflammatory diseases.
- | Preclinical, Journal: Deacetylation of HnRNP U mediated by sirtuin1 ameliorates aged rat with liver fibrosis via inhibiting p53-related senescence and NLRP3-related inflammation. (Pubmed Central) - Sep 17, 2024
Besides, the silence of SIRT1 aggravated H2O2-induced p53-related senescence and NLRP3-related inflammation in senescent hepatocytes. Our findings suggested that deacetylation of HnRNPU mediated by SIRT1 attenuated liver fibrosis in the elderly by inhibiting p53/p21 pathway and NLRP3-related inflammation.
- | LY294002 / Eli Lilly
Journal: MIF aggravates experimental autoimmune prostatitis through activation of the NLRP3 inflammasome via the PI3K/AKT pathway. (Pubmed Central) - Sep 17, 2024
Pharmacological inhibition of the PI3K/AKT pathway by LY294002 substantially reduced prostatic inflammation and macrophage infiltration, potentially by inhibiting NLRP3 inflammasome activation. These findings collectively suggest that MIF is a potential diagnostic marker for CNP and suggest that targeting MIF or its downstream signalling pathways, PI3K/AKT and NLRP3, might represent a novel therapeutic strategy for this condition.
- | Tenelia (teneligliptin) / Daiichi Sankyo, Mitsubishi Tanabe
Journal: Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy? (Pubmed Central) - Sep 16, 2024
These compounds may achieve this by elevating glucagon-like peptide-1 levels and potentially inhibiting the NLRP3 inflammasome. Further studies on teneligliptin in combination with other therapies targeting different aspects of DCM could be suggested for developing more effective treatment strategies to improve cardiovascular health in diabetic patients.
- | methamphetamine / Generic mfg.
Journal: Betaine improves METH-induced depressive-like behavior and cognitive impairment by alleviating neuroinflammation via NLRP3 inflammasome inhibotion. (Pubmed Central) - Sep 15, 2024
release. These results collectively suggest that betaine's significant role in mitigating depressive-like behavior and cognitive impairment resulting from METH abuse, presenting potential applications in the prevention and treatment of substance addiction.
- | Journal: Targeting the NLRP3 inflammasome in cochlear macrophages protects against hearing loss in chronic suppurative otitis media. (Pubmed Central) - Sep 15, 2024
protects OHCs in CSOM. Collectively, our data demonstrates that the main driver for hearing loss in CSOM is NLRP3 inflammasome activation in cochlear macrophages and this is therapeutically targetable, leading the way for the development of interventions to prevent the leading cause of permanent hearing loss and a costly disease in the developed world.
- | Bosulif (bosutinib) / Pfizer, Iclusig (ponatinib) / Takeda, Otsuka, Tasigna (nilotinib) / Novartis, Inhibikase
Journal: Investigation of the Role of NLRP3 Inflammasome Activation in New-Generation BCR-ABL1 Tyrosine Kinase Inhibitors-Induced Hepatotoxicity. (Pubmed Central) - Sep 15, 2024
Indeed, bosutinib and nilotinib were associated with severe hepatotoxicity compared with imatinib...This study aimed to investigate the role of NLRP3 inflammasome activation in the underlying mechanism of ponatinib and bosutinib-induced hepatotoxicity...In summary, NLRP3 inflammasome activation is involved in new-generation BCR-ABL1 TKIs-triggered hepatotoxicity. Mitochondrial damage and reactive oxygen species accumulation were significant upstream signaling events in this signaling pathway.
- | Journal: Tyrobp deficiency blocks NLRP3-mediated inflammation and pyroptosis to alleviate myocardial ischemia-reperfusion injury through regulating Syk. (Pubmed Central) - Sep 15, 2024
Mitochondrial damage and reactive oxygen species accumulation were significant upstream signaling events in this signaling pathway. Tyrobp deficiency alleviated MIRI by inhibiting NLRP3-mediated inflammation and pyroptosis through regulating Syk, providing a novel target for the treatment of MIRI.
- || Review, Journal: Inhibitors of NLRP3 Inflammasome Formation: A Cardioprotective Role for the Gasotransmitters Carbon Monoxide, Nitric Oxide, and Hydrogen Sulphide in Acute Myocardial Infarction. (Pubmed Central) - Sep 14, 2024
Therapies to prevent NLRP3 inflammasome formation in the clinic are currently lacking, and therefore, new pharmacotherapies are required. This review will highlight the role of the NLRP3 inflammasome within the myocardium during IRI and will examine the therapeutic value of inflammasome inhibition with particular attention to carbon monoxide, nitric oxide, and hydrogen sulphide as potential pharmacological inhibitors of NLRP3 inflammasome activation.
- | Journal: Kynurenine Attenuates Ulcerative Colitis Mediated by the Aryl Hydrocarbon Receptor. (Pubmed Central) - Sep 14, 2024
KYN could trigger AhR activation, inactivate the NF-?B signaling pathway, and inhibit NLRP3 inflammasome production, thus alleviating intestinal epithelial barrier dysfunction and reducing intestinal inflammation. In conclusion, the present study reveals that KYN ameliorates UC by improving the intestinal epithelial barrier and activating the AhR-NF-?B-NLRP3 signaling pathway, and it can be a promising therapeutic agent and dietary supplement for alleviating UC.
- | Preclinical, Journal: Salidroside promotes liver regeneration after partial hepatectomy in mice by modulating NLRP3 inflammasome-mediated pyroptosis pathway. (Pubmed Central) - Sep 14, 2024
Notably, SAL in combination with the NLRP3 inhibitor MCC950 did not further inhibit NLRP3 inflammasome and promote liver mass recovery. In summary, our findings proved that SAL could be a potential agent for improving liver function and promoting liver regeneration after PH.
- | Journal: ?2-Adrenoceptor agonist formoterol attenuates NLRP3 inflammasome activation and GSDMD-mediated pyroptosis in microglia through enhancing I?B?/NF-?B inhibition, SQSTM1/p62-dependent selective autophagy and ESCRT-III-mediated plasma membrane repair. (Pubmed Central) - Sep 14, 2024
Additionally, we showed that formoterol activates autophagy, autophagosome formation, and ESCRT-III-mediated plasma membrane repair, which are significant pathways in the inhibition of NLRP3 inflammasome activation and pyroptosis. Our study suggests that formoterol efficaciously prevents the NLRP3 inflammasome activation and pyroptosis in microglial cells regulation through I?B?/NF-?B, autophagy, autophagosome formation, and ESCRT-III-mediated plasma membrane repair.
- | acarbose / Generic mfg.
Journal: A Novel Dipterocarpol Derivative that Targets Alpha-Glucosidase and NLRP3 Inflammasome Activity for Treatment of Diabetes Mellitus. (Pubmed Central) - Sep 13, 2024
release. Additionally, compound 8 was shown to promote neuronal survival in LPS+ATP-treated rat hippocampal slices, highlighting its potential as a promising antidiabetic agent that targets both postprandial hyperglycemia and metaflammation.
- | belnacasan (VX-765) / Vertex
Preclinical, Journal: Glucose metabolite methylglyoxal induces vascular endothelial cell pyroptosis via NLRP3 inflammasome activation and oxidative stress in vitro and in vivo. (Pubmed Central) - Sep 13, 2024
Moreover, NLRP3 inhibitor (MCC950) and caspase-1 inhibitor (VX765) further reduced pyroptosis in endothelial cells that were pretreated with SFN. Collectively, these findings broaden our understanding of the mechanism by which SFN inhibits pyroptosis induced by MGO and suggests important implications for the potential use of SFN in the treatment of vascular diseases.
- | bortezomib / Generic mfg., dexamethasone / Generic mfg.
Journal: Function of NLRP3 inflammasome activation in multiple myeloma. (Pubmed Central) - Sep 13, 2024
2. Activation of NLRP3 inflammasome inhibits the early apoptosis of myeloma cells induced by dexamethasone and bortezomib.
- | belnacasan (VX-765) / Vertex
Journal: Epinephelus coioides NLRP3 inhibits SGIV infection by upregulating Capspase-1 activity. (Pubmed Central) - Sep 12, 2024
Furthermore, the NLRP3 inflammasome activator Nigericin was able to inhibit the infection of SGIV significantly. The above findings suggest that Ec-NLRP3 inhibits SGIV infection by upregulating caspase-1 activity.
- | Journal: PGC-1? inhibits NLRP3 signaling through transcriptional activation of POP1 to alleviate inflammation and strengthen osteogenic differentiation of lipopolysaccharide-induced human periodontal stem cells. (Pubmed Central) - Sep 12, 2024
Taken together, PGC-1? inhibits NLRP3 signaling through transcriptional activation of POP1, thereby alleviating inflammation and strengthening osteogenic differentiation of LPS-induced PDLSCs.
- | Journal: Apelin-13-Loaded Macrophage Membrane-Encapsulated Nanoparticles for Targeted Ischemic Stroke Therapy via Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis. (Pubmed Central) - Sep 12, 2024
The biocompatibility and safety of MM/ANPs were confirmed through in vitro cytotoxicity tests, blood-brain barrier permeability tests, biosafety evaluations, and blood compatibility studies. MM/ANPs offer a highly promising approach to achieve ischemic stroke-targeted therapy inhibiting NLRP3 inflammasome-mediated pyroptosis.
- | pilocarpine / Generic mfg.
Preclinical, Journal: NLRP3 Inflammasome Inhibition After Pilocarpine-Induced Status Epilepticus Attenuates Chronic Inflammation in Epileptic Mice. (Pubmed Central) - Sep 12, 2024
Inhibition of NLRP3 inflammasome post-SE effectively ameliorates neuronal loss, seizure susceptibility, and cognitive dysfunction during epileptogenesis. This neuroprotective effect may be mediated through the mitigation of chronic pro-inflammatory responses within the epileptic brain.
- || Review, Journal: Recent advances in the treatment of gout with NLRP3 inflammasome inhibitors. (Pubmed Central) - Sep 11, 2024
In recent years, there has been significant academic and industrial interest in the development of NLRP3-targeted small molecule inhibitors as a promising therapeutic approach for gout. To assess the advancements in NLRP3 inflammasome inhibitors for gout treatment, this review offers a comprehensive analysis and evaluation of current clinical candidates and other inhibitors targeting NLRP3 inflammasome from a chemical structure standpoint, with the goal of identifying more efficacious options for clinical management of gout.
- | Journal: Proliferative mechanism of benign prostatic hyperplasia by NLRP3 inflammasome through the complement pathway. (Pubmed Central) - Sep 11, 2024
and IL-18 through Caspase-1 during the BPH proliferative process. NLRP3 inflammasome have the possibilities to be a therapeutic target for BPH proliferation by inhibiting the NLRP3 inflammasome pathway.
- | azithromycin / Generic mfg.
Journal: Yinqin Qingfei granules alleviate Mycoplasma pneumoniae pneumonia via inhibiting NLRP3 inflammasome-mediated macrophage pyroptosis. (Pubmed Central) - Sep 11, 2024
Lentivirus transfection and immunofluorescence double staining confirmed that YQQFG significantly suppressed NLRP3 expression in macrophages, outperforming azithromycin (AZM)...YQQFG mitigates inflammatory responses by suppressing NLRP3 inflammasome-mediated macrophage pyroptosis, thereby ameliorating MP-induced acute lung injury. YQQFG serves as an effective adjunct and alternative medication for pediatric MPP treatment.
- | Journal: ?-Caryophyllene mitigates ischemic stroke-induced white matter lesions by inhibiting pyroptosis. (Pubmed Central) - Sep 10, 2024
In addition, nigericin significantly exacerbates neurological outcomes and increases white matter lesions following BCP treatment in middle cerebral artery occlusion (MCAO) mice. These results suggest that BCP may ameliorate neurological deficits and white matter damage induced by cerebral ischemia through inhibiting NLRP3-mediated pyroptosis.
- | Journal: Sestrin2 plays a protective role in Age-related hearing loss by inhibiting NLRP3-inflammasome activity. (Pubmed Central) - Sep 10, 2024
Importantly, we elucidated that SESN2 exerts a hearing-protective effect by inhibiting the production of NLRP3 by acting as a mitophagy agonist. Our study proposes a new theoretical basis for SESN2 prevention of ARHL and provides a novel therapeutic strategy for maintaining SESN2 activity in the aging cochlea.